Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00415064 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma

A Phase 1 study of Multiple Myeloma, sponsored by AEterna Zentaris.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT00415064: Completed Phase 1 study of Multiple Myeloma, sponsored by AEterna Zentaris.

NCT00415064 is a Phase 1 study of Multiple Myeloma that has completed, run by AEterna Zentaris. The registered enrollment target is 32 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00415064, a Phase 1 study of Multiple Myeloma, has completed, sponsored by AEterna Zentaris.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. The current protocol will enroll patients with relapsed or refractory multiple myeloma requiring second or third line therapy. Six patients each will be treated with at one of 4 dose levels in a phase 1 study. All patients will receive perifosine, lenalidomide and dexamethasone of each 28 day cycle. The doses of perifosine and lenalidomide will be varied in each group. The dose of dexamethasone will remain constant.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Perifosine

Study Locations (1)

Michigan

  • - Ann Arbor

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2006-12
Est. Completion 2012-07
Phase Phase 1
AEterna Zentaris

21 total trials

What the finished NCT00415064 record still lists

NCT00415064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT00415064 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT00415064 about?

NCT00415064 is a clinical study titled "Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma". This is a phase I study of perifosine in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. The current protocol will enroll patients with relapsed or refractory multiple myeloma requiring second or third line therapy. Six patients each will be...

What is the current status of trial NCT00415064?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-12. Estimated completion is 2012-07.

What conditions does trial NCT00415064 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00415064?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Perifosine (DRUG).

Who is sponsoring clinical trial NCT00415064?

This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00415064 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00415064's enrollment target sits among peer trials

32 324th of 438 higher than 104 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00415064, the US trial registry maintained by the National Library of Medicine. NCT00415064 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.